(Photo Credit: Srdjan Randjelovic/Shutterstock)
Did you or a loved one develop lymphoma after starting Dupixent injections? You may be eligible to take legal action and seek compensation. Complete the confidential form on this page to learn more about the Dupixent lawsuit.
Dupixent is a prescription medication commonly used to treat eczema, asthma and other inflammatory conditions. While it has helped many patients manage their symptoms, recent clinical reports have linked Dupixent injections to rare but serious cancers, including Cutaneous T-Cell Lymphoma (CTCL) and related T-cell lymphomas.
If you or a loved one received Dupixent and were later diagnosed with CTCL or another lymphoma, it is important to understand your legal options, including whether you may qualify for a Dupixent lawsuit.
Do you qualify?
If you received Dupixent injections for 3 to 6 months and were later diagnosed with CTCL or any of the following cancers, you may be eligible to file a Dupixent lawsuit:
Cutaneous T-Cell Lymphoma (CTCL)
Mycosis Fungoides
Sézary Syndrome
Lymphomatoid Papulosis
Anaplastic Large Cell Lymphoma
Extranodal Natural Killer (NK) T-Cell Lymphoma
Subcutaneous Panniculitis-Like T-Cell Lymphoma
Adult T-Cell Leukemia/Lymphoma
Follicular Helper T-Cell Lymphoma
Peripheral T-Cell Lymphoma
To determine if you qualify, please complete the confidential form on this page.
Fill out the form on this page for more information.
What is Dupixent and how is it linked to Cutaneous T-Cell Lymphoma?
Dupixent is a prescription injectable medication commonly used to treat eczema (atopic dermatitis), asthma, chronic obstructive pulmonary disease (COPD), and other inflammatory conditions. It works by targeting specific proteins in the immune system to reduce inflammation and is approved for use in adults and children as young as six.
While Dupixent can be effective for these conditions, recent clinical reports have identified cases in which patients developed Cutaneous T-Cell Lymphoma (CTCL) after starting the medication. In many instances, these diagnoses occurred within a year of the first Dupixent injection.
Types of cancer potentially linked to DupixentÂ
Research and clinical reports have suggested a potential link between Dupixent and several types of rare blood and skin cancers. Individuals who have received Dupixent and were later diagnosed with any of the following conditions may qualify to take part in a Dupixent lawsuit:
Cutaneous T-Cell Lymphoma (CTCL)
Mycosis Fungoides
Sézary Syndrome
Lymphomatoid Papulosis
Anaplastic Large Cell Lymphoma
Extranodal Natural Killer (NK) T-Cell Lymphoma
Subcutaneous Panniculitis-Like T-Cell Lymphoma
Adult T-Cell Leukemia/Lymphoma
Follicular Helper T-Cell Lymphoma
Peripheral T-Cell Lymphoma
How to file a Dupixent lawsuit
If you or a loved one received a CTCL diagnosis that may be linked to Dupixent injections, you could be eligible to take legal action.
To begin the process, please complete the confidential form on this page to share your experience. A legal professional will review your case and may contact you to discuss your options.
Fill out the form on this page to see if you qualify for a free case evaluation.
The law firms responsible for the content of this page are: Accident Injury Lawyers, PA / 866-481-5347 / dolmanlaw.com, and LegaFi Law LLC (an Arizona law firm) / 888-4-LegaFi / www.legafi.com